BlueRock Therapeutics Entered into a Collaboration and Option Agreement with bit.bio to Discover and Manufacture Regulatory T cell (Treg) Based Therapies
Shots:
- bit.bio receives an up front and is eligible to receive milestones along with royalties on global sales of all therapies that resulted from the collaboration. BlueRock will lead the global development & commercialization of therapeutic candidates
- The collaboration focuses to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs by using bit.bio's machine learning-powered discovery platform
- BlueRock also gets an option to license bit.bio's opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies. bit.bio uses opti-ox to drive the rapid TF-mediated conversion of iPSCs into highly defined cell types in a single step
Ref: PR Newswire | Image: BlueRock
Related News:- Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
